Heartflow, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HTFL research report →
Range $40 – $70
Price Chart
About the company
HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart.
- CEO
- John Farquhar
- IPO
- 2025
- Employees
- 843
- HQ
- San Francisco, CA, US
Get TickerSpark's AI analysis on HTFL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.10B
- P/E
- -48.51
- Fwd P/E
- 784.10
- PEG
- -0.77
- P/S
- 16.44
- P/B
- 13.78
- EV/EBITDA
- -54.28
- Div Yield
- 0.00%
- Gross Margin
- 81.85%
- Op Margin
- -29.97%
- Net Margin
- -33.11%
- ROE
- -27.52%
- ROIC
- -23.13%
Latest fiscal year · YoY change
- Revenue
- $176.03M+39.9%
- Gross Profit
- $135.20M+43.1%
- Op Income
- $-64,066,000
- Net Income
- $-116,791,000-21.1%
- EPS
- $-1.37+10.5%
- OCF Growth
- +21.7%
- FCF Growth
- +19.5%
- 52W High
- $60.66
- 52W Low
- $20.13
- 50D MA
- $51.83
- 200D MA
- $35.56
- Beta
- 2.02
- RSI (14)
- 36
- Avg Volume
- 1.85M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
HeartFlow delivered a strong Q3 with 57% revenue growth, margin expansion, and a raised full-year outlook as Plaque and FFRCT both gained momentum.· November 12, 2026
- Q3 revenue was $72.9 million, up 57.4% year over year, with U.S. revenue up 60% to $67.9 million.
- Gross margin expanded to 83.8% from 76.8% a year ago, helped by volume leverage, Plaque mix, and AI-driven production efficiency.
- Full-year 2026 revenue guidance was raised to $262 million to $264 million, and Plaque revenue guidance was raised to $36 million to $37 million.
- Management now expects about 1,300 Plaque activate accounts by year-end and more new account activations in 2026 than the 340 added in 2025.
- The company reiterated confidence in reaching its midterm 85% gross margin target and cash flow profitability by mid-2028.
Total revenue in Q3 2026 was $72.9 million, up 57.4% year over year. U.S. revenue was $67.9 million, up 60%, including $11.8 million of Plaque revenue; OUS and other revenue was $4.9 million. Total global revenue cases were 98,155, up 89.5%. Non-GAAP gross margin was 83.8% versus 76.8% in Q3 2025. Non-GAAP net loss was $2.7 million, or $0.03 per share, versus $13.2 million, or $0.27 per share a year ago; GAAP net loss was $11.5 million, or $0.13 per share. For 2026, management raised total revenue guidance to $262 million to $264 million, implying 49% to 50% growth, and raised Plaque revenue guidance to $36 million to $37 million. Full-year non-GAAP gross margin guidance was raised to approximately 82.5%, up 550 basis points year over year, and non-GAAP operating expenses as a percentage of revenue are expected to decline by greater than 5 points year over year.
John Farquhar said Q3 was an “outstanding quarter,” with year-over-year revenue growth accelerating for the third straight quarter and the business finishing ahead of expectations. He emphasized strong Plaque adoption, durable FFRCT utilization, strong new account adds, and a growing CCTA market, calling the platform the company’s “complete solution” from first scan through PCI planning. His tone was confident and upbeat, especially around recent clinical data, Boston Scientific collaboration, and the belief that the company is moving toward becoming the new standard of care.
Vikram Verghese highlighted that Q3 revenue rose to $72.9 million, gross margin reached 83.8%, and non-GAAP operating loss narrowed to $5 million from $11.1 million a year ago. He said the margin improvement came from volume leverage, higher Plaque revenue, and AI-enabled production efficiency, while SG&A was $39.3 million and R&D was $26.8 million as the company continued targeted investment. He also noted $253 million in cash, cash equivalents and investments, said the balance sheet can fund operations through profitability, and reiterated a path to 85% gross margin and cash flow profitability by mid-2028.
Analysts focused on how much of the growth came from existing versus new accounts, the impact of the P4 and DECIDE data, Q4 seasonality, Plaque pricing and contract renewals, and the company’s 2027 profitability and growth profile. Management said FFRCT and Plaque are both seeing strong utilization in new and existing accounts, that P4 and NAVIGATE-PCI have increased interest in PCI Navigator, and that DECIDE is a positive tailwind for Plaque adoption and physician education. On guidance, they said Q4 should still show strong demand, but pricing assumptions are conservative, holiday seasonality is included, and most 2026 Plaque price increases are already behind them.
The call showed broad-based momentum: FFRCT remains durable, Plaque adoption is ramping, and new account adds are running ahead of last year. Management also pointed to meaningful clinical and commercial catalysts, including DECIDE outcomes data, P4 randomized trial results, and the Boston Scientific collaboration, all of which they believe strengthen the CT-first HeartFlow pathway.
Management acknowledged that Plaque pricing increases are largely behind them in 2026 and that Q4 will face normal holiday seasonality, which could temper near-term growth. They also cautioned that Plaque remains early in its adoption curve, utilization is still far below the theoretical ceiling, and they do not expect a “hockey stick” ramp. Longer term, the high-risk asymptomatic trials are still ahead, with data expected by the end of 2028, so that growth wave remains unproven for now.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 77.6%
- Shares Outstanding
- 87.89M
- Float Shares
- 68.22M
of shares held by institutions
201 13F filers
Buy/sell ratio 0.28. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 8.45M | ▼ 2.00M |
| Wellington Management Group Llp | 7.86M | ▼ 4.12M |
| Blackrock, Inc. | 6.04M | ▲ 843.20K |
| Fmr LLC | 5.49M | ▲ 670.33K |
| Vanguard Portfolio Management LLC | 3.72M | ▲ 135.04K |
| Vanguard Capital Management LLC | 3.32M | ▲ 562.48K |
| Bamco Inc | 3.23M | ▼ 602.40K |
| Invesco Ltd. | 2.69M | ▲ 394.53K |
| Jupiter Topco LLC | 2.42M | ▲ 2.42M |
| Janus Henderson Group Ltd. | 2.18M | ▲ 1.32M |
| Alliancebernstein L.P. | 1.92M | ▲ 699.94K |
| Geode Capital Management, LLC | 1.82M | ▲ 456.99K |
Held by 261 ETFs
Biggest fund positions in HTFL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Rogers Campbell | other | 5,101 |
| Nov 17, 26 | Rogers Campbell | other | 12,328 |
| Nov 17, 26 | Rogers Campbell | sell | 24,188 |
| Nov 17, 26 | Rogers Campbell | other | 5,101 |
| Feb 20, 26 | Rogers Campbell | sell | 16,918 |
| Sep 18, 26 | Rogers Campbell | sell | 6,503 |
| Sep 18, 26 | Rogers Campbell | sell | 5,653 |
| Mar 19, 26 | Rogers Campbell | sell | 16,918 |
| Oct 22, 26 | Rogers Campbell | sell | 6,503 |
| Oct 22, 26 | Rogers Campbell | sell | 5,654 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HTFL coverage
Recent articles, reports, and earnings notes.
No research on HTFL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HTFL report →HeartFlow: A Post Q3 Assessment
seekingalpha.com · Nov 17
HeartFlow: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 13
HeartFlow, Inc. (HTFL) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
What Heartflow (HTFL) Said on Its Q3 Earnings Call
marketbeat.com · Nov 12
HeartFlow (HTFL) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 12
Heartflow Reports Third Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
globenewswire.com · Nov 12
Voya Small Cap Growth Strategy Q3 2026 Contributors And Detractors
seekingalpha.com · Nov 12
Heartflow (NASDAQ:HTFL) Stock Rating Lowered by Wall Street Zen
defenseworld.net · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.